Calyxt

Canaccord Genuity acted as Sole Bookrunner on a $10.9 million offering of common shares and warrants on behalf of Calyxt, Inc. (NASDAQ: CLXT)

Canaccord Genuity is pleased to announce that on February 23, 2022, Calyxt (Nasdaq: CLXT) closed its previously announced offering of common shares for gross proceeds of $10.9 million (the “Offering”). The net proceeds from the Offering will be used to enhance the capabilities of Calyxt’s BioFactory™ production system, increase the BioFactory™ capacity, build out its PlantSpring™ technology platform and AIML capabilities, further customer relationships and for working capital and general corporate purposes.

Calyxt (Nasdaq: CLXT) is a plant-based synthetic biology company. The Company uses metabolism to produce innovative and high value plant-based chemistries for use in customers’ materials and products. As plant-based solutions, the Company’s synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system.

The Canaccord Genuity team included Jen Pardi, Brian O’Connor, Tom Gabel, Morgan Ley, Michael Wright, Brooke Szczygiel, Bronwyn Davies, and Catherine Guanci.